A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Intravenous Infusion and Subcutaneous Administration of TAK-079 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 May 2017
At a glance
- Drugs TAK 079 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Takeda
- 20 Jun 2016 Status changed from active, no longer recruiting to completed.
- 02 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.
- 02 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.